Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Drilling at Pt. Leamington unveils a copper-rich extension, targeting near-surface high-grade zones (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Neurosense Therapeutics Ltd NRSN

Alternate Symbol(s):  NRSNW

Healthcare Biotechnology
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.


NDAQ:NRSN - Post by User

Neurosense Therapeutics Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1069)
•••
  • IseneschalX
Post by Iseneschalon Apr 08, 2022 9:11am
110 Views
Post# 34587309

NRSN .... Happy "Fryday" Folks....

NRSN .... Happy "Fryday" Folks....Looking for continued weakness in this maniped deal.

This is "Spear-catching" at it's finest ; )

How low can this go...... ya pays yo money and yo takes yo chances

 Cheers !
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities